Specifications Manual for Joint Commission National Quality Measures (v2018A)
Home » Procoagulant Reversal Agent Initiation

Release Notes:
Data Element
Version 2018A

Data Element Name: Procoagulant Reversal Agent Initiation
Collected For: CSTK-04
Definition:A procoagulant reversal agent was initiated at this hospital. Procoagulant reversal agents are medications that increase coagulation factors to promote clotting.
Suggested Data Collection Question:Is there documentation that a procoagulant reversal agent was initiated at this hospital?
Format:
Length:1
Type:Alphanumeric
Occurs:1
Allowable Values:

Y (Yes) A procoagulant reversal agent was initiated at this hospital.

N (No) A procoagulant reversal agent was not initiated at this hospital, OR unable to determine from medical record documentation.
Notes for Abstraction:
  • If a procoagulant reversal agent was initiated at this hospital, select “Yes”.
  • Only accept reversal agents identified in the list of inclusions. No other terms for reversal agents will be accepted.
  • If Vitamin K only was administered as the sole form of reversal and no other procoagulant agent was administered, select “No”.
Suggested Data Sources:

  • Emergency department record
  • Nursing flow sheet
  • Progress notes
  • Medication administration record (MAR)
  • Medication reconciliation form
Additional Notes:
Guidelines for Abstraction:
Inclusion Exclusion
  • Activated prothrombin complex concentrates
  • Anti-inhibitor coagulant complex
  • Autoplex T
  • Bebulin VH
  • Eptacog alfa
  • Factor IX Complex
  • Factor VIIa (Recombinant)
  • Feiba VH Immuno
  • Fresh frozen plasma (FFP)
  • NovoSeven
  • NovoSeven RT
  • Profilnine SD
  • Proplex T
  • Prothrombin complex concentrates (PCCs
  • rFVIIa
  • (Kcentra) PCC-Human
  • Pradaxa (dabigatran) reversal agent: Praxbind (idarucizumab)
  • Vitamin K Only
  • Factor IX (without complex)

Procoagulant Reversal Agent Initiation
Specifications Manual for Joint Commission National Quality Measures (v2018A)
Discharges 07-01-18 (3Q18) through 12-31-18 (4Q18)
^